Clinical Trials Logo
  1. Home
  2. Glaucoma
  3. NCT00950690
  4. Details
NCT00950690 Clinical Trial

Efficacy and Tolerability of Xalatan in Patients

Glaucoma Clinical Trial

— A6111128  

Official title:
Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00950690
Other study ID # A6111128
Secondary ID A6111128
Status Completed
Phase
First received
Last updated
Start date July 2005
Est. completion date December 2007

Study information
Verified date February 2011
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.

Description:

- Efficacy data not collected or analyzed - Safety and tolerability of Xalatan assessed NA

Recruitment information / eligibility
Status Completed
Enrollment 1289
Est. completion date December 2007
Est. primary completion date December 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patient with ocular hypertension at least 22mg Hg - Patient must be over 18 years old Exclusion Criteria: - None listed in the protocol

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Xalatan 0.005% eye drops
ophthalmic solution dosed once daily for 3 months

Locations
Country Name City State
Egypt Pfizer Investigational Site Alexandria
Saudi Arabia Pfizer Investigational Site Jeddah
United Arab Emirates Pfizer Investigational Site Umm Al Quwain

Sponsors (1)
Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Countries where clinical trial is conducted

Egypt,  Saudi Arabia,  United Arab Emirates, 

Outcome
Type Measure Description Time frame Safety issue
Primary Intraocular Pressure Intraocular pressure was measured at each visit Screening, 10 days, 4 weeks and 12 weeks after beginning treatment
Primary Humphrey Perimetry Visual Field Analysis of visual field deficits for abnormalities. Visits 1 and 4
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A

External Links